Slide 1
|
L00 Welcome - Specht TP |
1 |
|
L01 The Role of Radiation Oncologist - Specht |
14 |
|
L02 Radiation Therapy - Specht |
36 |
|
L03 Immunotherapy and New Immunological Approaches - Illidge |
90 |
|
L04 Long-term Toxicity of Radiation Therapy - Aleman |
151 |
|
L05 Chemotherapy and Combined Modality Treatments - Engert |
229 |
|
L06 Hodgkin Lymphoma, Lymphocyte Predominance - Mikhaeel |
280 |
|
L07 Primary Treatments - Illidge |
319 |
|
L08 Advanced Stage and Relapsed-Refractory Disease - Engert |
380 |
|
L09 Relapsed-Refrectory Disease - Mikhaeel |
431 |
|
L10 Radiation Therapy for Hodgkin Lymphoma - Ricardi |
455 |
|
L11 Primary Treatment; Indolent Nodal Non Hodgkin - Illidge |
511 |
|
L12 Radiation Therapy for Indolent Nodal Lymphomas - Ricardi |
604 |
|
L13 Motion Management and DIBH - Specht-Aznar |
660 |
|
L14 The Principles of the use of Systemic Treatment in non-Hodgkin Lymphomas - Davies |
697 |
|
L15 Early Stage; Aggressive Nondal Non Hodgkin - Ricardi |
798 |
|
L16 Advanced Stage and Relapsed-Refractory Disease -Davies |
854 |
|
L17 Radiation Therapy for Aggressive Lymphomas - Mikhaeel |
948 |
|
L18 Head and Neck - Specht |
1032 |
|
L19 Thyroid - Mikhaeel |
1063 |
|
L20 Orbital - Ricardi |
1079 |
|
L21 CNS - Aleman |
1123 |
|
L22 Gastric - Specht |
1176 |
|
L23 Systemic Approaches to Early and Advanced Marginal Zone Lymphoma - Davies |
1192 |
|
L24 Lung - Ricardi |
1253 |
|
L25 Bone - Ricardi |
1281 |
|
L26 Myeloma - Ricardi |
1310 |
|
L27a Imaging for Radiotherapy of Lymphomas - Mikhaeel |
1364 |
|
L27b lmaging for Radiotherapy of Lymphomas - Berthelsen |
1452 |
|
L28 Breast - Aleman |
1487 |
|
L29 Skin - Specht |
1519 |
|
L30 Testicular - Aleman |
1551 |
|
L31 Other Rare Sites - Mikhaeel |
1570 |
|
L32 Splenomegaly - Specht |
1589 |
|
L33 Leukemia - Specht |
1595 |
|
L34 Farewell - Specht |
1625 |